Articles On Medlab Clinical (ASX:MDC)

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

There was plenty of action in the US regulatory front within the cannabis sector this week. A couple of major legislations during the week could potentially shake up the US cannabis industry. The Marijuana Opportunity Reinvestment and Expun...

The outlook of the the ‘Horizons Marijuana Life Sciences Index ETF’ (HMMJ) staged a comeback last week — showing a 25.13% gain after suffering a steep decline earlier this month — while news broke that New York and New Jersey may be facing...

In 2021, which of Europe and North America is the place to be for ASX cannabis stocks?   The case for Europe A few years ago there would’ve been no question that it was North America with Canada legalising recreational cannabis as well as h...

A cannabis-based drug has been listed on Australia’s Pharmaceutical Benefits Scheme for the first time, as medical marijuana gains increased acceptance. The move means that an estimated 116 Aussies with a rare form of epilepsy known as Drav...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

The “hottest ASX stock” – in other words, the stock with the highest RSI – this week is Rumble Resources (ASX:RTR). Each week Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a t...

April 20 has come and gone, but ASX cannabis companies aren’t getting that high — they’re actually low. Of the 36 pot companies in the space, 27 have lost ground over the last fortnight. Just seven have advanced. Gains were led by Wide Open...

Summary Health House International has signed a non-exclusive distribution agreement with Dragonfly Biosciences. The agreement with Dragonfly would strengthen Health House’s product portfolio within Australia. The distribution agreeme...

Source: photolona, Shutterstock Summary Australian Primary Hemp has signed another retail distribution agreement with Coles Group Limited. Cannabis player Little Green Pharma has entered into a non-exclusive distribution agreement wit...

The Horizons Marijuana Life Sciences Index ETF (HMMJ) ebbed lower this week after rebounding at the start of the April — while still exceeding its six month performance by more than 80% — despite news that lawmakers in Virginia have elected...

Cannabis centric healthcare company Bod Australia Limited (ASX:BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021. Mr Dw...

Australian biotech Medlab Clinical (ASX: MDC) has reported the first cohort of patients undergoing a 12-month study of its NanaBis cannabinoid treatment for cancer-induced bone pain have registered a dramatic improvement in their pain score...

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

The Medlab Clinical Ltd (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant the Australian company a patent for its Nanocelle technology. The Medlab share price is up 8.33% today to 26 c...

Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a patent covering the use of the company’s NanoCelle drug delivery platform. The patent, filed in 2...

Wall Street slides, as IMF raises global growth forecast All major US indices slid on Tuesday, but stayed near record highs gained the previous day. Dow Jones closed 0.29% lower, S&P500 dropped 0.1%, while tech heavy NASDAQ slid 0.05%....

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

The managing director of Novartis Oncology for Australia and New Zealand, Cheryl Maley, has been appointed to the board of Australian biotechnology company Medlab (ASX:MDC).

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment of “leading” pharmaceutical executive Cheryl Maley. The company announced on Friday it had rais...

The ASX saw the best IPO debut of the year to date in manganese explorer Firebird Metals (ASX:FRB), which rose 198 per cent on debut. This beat the previous 2021 record held by WA telco Pentanet (ASX:5GG), which finished its first day in la...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

Source: Joyseulay, Shutterstock After a tepid trading session in Wall Street yesterday, the Australian market had a volatile session today. The benchmark index ASX 200 closed at 6785 points with a drop of 41.80 points, a marginal decline o...

The ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks lost over 1 per cent each while Tech was the best sector gaining 0.70 per cent. Large caps fared worse than small caps with the ASX 200 losi...

Source:Eviart, Shutterstock In the initial trading on Wednesday, the market followed yesterday's pattern and continued with the volatile trading session. After some early gains, it fell steeply and continues to lose points. Most of the...

Medical research and development outfit Medlab Clinical is on the hunt for an equity injection to help fund clinical trails for its chronic disease-treating therapies. 

The share price of Medlab Clinical Ltd [ASX:MDC] is down more than 2%, trading at 33.5 cents. After an impressive run-up, the MDC share price is now starting to move closer to its January heights where it went as high as 42 cents... The po...

Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue from Special Access Scheme (SAS) sales of its NanaBis and NanoCBD products along with ongoing nu...

Summary The ASX 200 was trading in red towards the end of the session, down 80 points to 6,884.40 on Thursday. Most of the sectors were trading in the red. Health Care led the gains in the ASX 200 index, followed by Banks, Consumer Dis...

Summary Medlab Clinical has entered in an exclusive non-binding agreement with Australia’s largest generic pharmaceutical and OTC medicines company. This is the first partnership between a pharma and a biotech company investigating med...

The Medlab Clinical Ltd (ASX: MDC) share price is on the rise in mid-afternoon trade. This comes after the company announced an agreement with Australia’s largest generic and over the counter pharmaceutical company, Arrotex. Consequently,...

Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-track availability of its proprietary cannabinoid formulation NanoCBD throughout Australian pharma...

Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic to help treat major depression has revealed a “significant” reduction in depression. The trial involved administering NRGBiotic to patients dia...

ASX-listed cannabinoid stocks are poised for a resurgence after global biopharmaceutical company Jazz Pharmaceuticals lobbed a US$7.2 billion (A$9.4 billion) offer for UK-based medicinal cannabis drug developer GW Pharmaceuticals amid a sof...

Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outperforms opioids for cancer-related pain management, should its upcoming phase three trials be succ...

Summary Medical research and development company Medlab Clinical provided a quarterly update highlighting its business and quarterly cash flow report. Medlab stated that with the IND approval, it would initiate NanaBis™ pivotal Phase I...

Summary Australian based medical life science company Medlab Clinical has obtained an IND grant for NanaBis™ from the US FDA. With the FDA approval, Medlab can initiate its pivotal Phase 3 clinical trial at US sites. The Company has a...

Small caps bounced back solidly from yesterday’s losses with the Small Ordinaries index finished Tuesday up 1.58 per cent to 3,123.7. The ASX 200 rose by 1.19 per cent to 6,742.6 however the Emerging Companies nano-cap index only rose by 0....

Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lead candidate NanaBis, which is designed for treating cancer-related pain. IND status from the FDA...

Medlab Clinical CEO Dr Sean Hall speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.

The New Criterion's Tim Boreham ascertains the impact a proposed regulatory change to medical cannabis will have on the market. By Tim Boreham, Editor, The New Criterion A new world beckons for the listed medical cannabis stocks, but libera...

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the a...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes for the week It’s been...

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...